Topical Delivery Of Hybrid Antimicrobial Peptide For Managing Acinetobacter Infected Wounds: A Novel Therapeutic Option | 51349
Journal of Infectious Diseases & Therapy
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Multidrug resistant Acinetobacter baumannii is recognized to be among the most difficult antimicrobial resistant Gram
negative bacilli to control and treat. It survives for prolonged periods under a wide range of environmental conditions and
causes outbreaks of serious infections including bacteremia, pneumonia, meningitis, urinary tract infection and wound infection.
Antimicrobial resistance greatly limits the therapeutic options for patients who are infected with this organism. Therefore, there is
a need to look for alternate treatment options like bio-therapeutics including antimicrobial peptides of prokaryotic or eukaryotic
origin. In the light of the present scenario, efficacy of a designer alpha helical peptide, a hybrid of cecropin, melittin and magainin
2 was evaluated. In vitro effectiveness of the peptide against A. baumanii was evaluated by determining the Minimum Inhibitory
Concentration which was found to be in the range of 2-4 μg/ml. To get an insight of mode of action of this peptide, various techniques
like Transmission Electron Microscopy, Scanning Electron Microscopy, Confocal microscopy and Flow cytometry were employed.
The SEM and TEM studies indicated that the peptide could bring significant morphological changes like damaged membrane and
leakage of cytoplasmic content. Furthermore, Confocal microscopy and Flow cytometry confirmed that membrane permeabilization
of A. baumanii cells by the hybrid peptide in a time dependant process. Inspired by the in vitro findings, therapeutic potential of this
peptide was evaluated in murine excision wound model infected with A. baumanii. For this, a hydrogel formulation was prepared
for evaluating its efficacy in terms of body weight, wound size contraction, bacterial load and histo-architectural alterations. Results
were recorded on day 1, 3,7,15 and 21 post-infection. There was a significant decrease in the body weight of mice that were infected
with A. baumanii whereas the loss was restored in the treatment group. The bacterial burden in the treatment group was significantly
reduced in comparison to the untreated group. A speedy contractile healing of the wound was observed in case of the group receiving
the treatment which further correlated well with the histological studies. The observations from the study indicate that the peptide
appears to be a good therapeutic option for developing newer treatment strategies against multidrug resistant strains.
Praveen Rishi has completed her PhD from Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Presently, she is the Chairperson of the Department of Microbiology, Panjab University, India. She has more than 100 publications in journals of repute and a Patent to her credit. She is a Fellow of Association of Microbiologists of India (FAMI) and Fellow of Indian Association of Biomedical Scientists (FABMS). She is also a recipient of Dr. Y.S. Narayana Rao Oration Award, conferred by Indian Council of Medical Research (ICMR). She is serving as an Editorial Board Member of various journals of repute.